Why Does a Dedicated Oncology Pharmacist Matter? A 62% Reduction in Side Effect Risk

📌 Why Does It Matter?

Cancer medicines are critical for extending patients’ lives and controlling disease. However, these drugs often come with serious adverse drug reactions (side effects) . These effects not only reduce quality of life, but can also interrupt treatment, cause hospitalization and even increase the risk of death.

Modern oncology treatments, particularly in hematology-oncology, involve many drug combinations and complex dose adjustments. This increases the risk of medication errors and therefore side effects. At this point, integrating a pharmacist specializing in oncologyinto treatment can play a key role in medication safety.

On August 1, 2025, JCO Oncology Practice published a new randomized controlled trial showing that adding a designated pharmacist to the hematology-oncology team dramatically reduced side effect risk and increased detection of potentially serious medication errors.

📊 Findings — Summary

• The likelihood of any side effect decreased by 62% — Among patients receiving pharmacist support, risk was AHR 0.38 (95% confidence interval 0.23–0.65; p<0.001).
• Risk of moderate or severe side effects decreased by 75% — In these patients, risk was AHR 0.25 (95% confidence interval 0.09–0.67; p=0.006).
• 95% of 588 pharmacist recommendations were implemented.
• 287 medication errors were detected; the proportion of potentially serious errors was higher (p=0.003).
• Detection of administration errors increased 2.6-fold (IRR 2.61; 95% CI 1.38–4.92; p=0.003).

AHR means Age-Adjusted Hazard Ratio (hazard ratio adjusted for age).

In brief, it is a statistical measure showing how much less or more often an event (such as a side effect) occurs in a group after accounting for the effects of age differences.

• AHR 1 → Same risk

• AHR < 1 → Reduced risk

• AHR > 1 → Increased risk

🔬 Study Summary

• Type: Parallel, randomized controlled clinical trial
• Duration: July 2020 – October 2022; Follow-up: 4 months of intervention + 1 month of monitoring
• Setting: Clalit Health Services, hematology-oncology outpatient clinics (Israel)
• Participants: 182 patients (91 intervention, 91 control)
• Intervention: A pharmacist reviewed treatment plans, provided counseling and made recommendations to physicians
• Assessment: Independent pharmacologist physicians classified recommendations as “medication errors” and rated their severity

💡 Clinical Practice and Interpretation

Integrating oncology-trained pharmacistsinto oncology clinics means lower side effect rates, with potentially serious medication errors more effectively detected and prevented. For patients with complex multidrug regimens and high toxicity risk in particular, this is a critical step toward ensuring safe treatment.

The data show that pharmacists are highly effective not only at detecting errors, but also at offering recommendations to improve treatment. A recommendation implementation rate as high as 95% demonstrates the strength of physician–pharmacist collaboration. This is concrete evidence that patient safety can improve substantially when clinical team members have complementary professional roles.

From an interpretive perspective, future cost-effectiveness analyses of this model could provide a strong foundation for health policies making “pharmacist integration” part of standard care. It will also be important to see whether similar results can be achieved in solid tumors as well as hematological malignancies.

This approach is therefore a strategy with substantial potential to improve patient safety and treatment success. Pharmacists’ participation in multidisciplinary oncology teams should be considered an essential component of treatment rather than simply “extra support.”

⚠️ Limitations

• Its single-center design and focus on hematological malignancies may limit generalizability.
• Side effects were based on physician documentation ; no patient reporting or doctor feedback was collected.
• For some secondary outcomes, such as emergency visits and hospital admissions, statistical power was limited.
• Cost-effectiveness or reimbursement impact was not analyzed.

In summary: The “designated oncology pharmacist” model is a powerful tool for patient safety and medication safety ; scalability and cost-effectiveness should be clarified in future studies.